Allergy

AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.

Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.

In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.

AAAAI 2025. Treatment response rates with daily use of the VIASKIN peanut patch increased from 39% at baseline to 73.3% at 60 months in youth aged 4 to 11 years.

Researchers at Phoenix Children’s Hospital conducted one of the largest real-world clinical evaluations of the esophageal string test in children.

Your daily dose of the clinical news you may have missed.

If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.

Treatments with the investigational rescue medication achieved clinically effective epinephrine levels faster than intramuscular injection.

The updated guidelines include 19 recommendations related to the diagnosis and management of eosinophilic esophagitis.

Aquestive Therapeutics announced positive feedback from the FDA this week that keeps NDA planning for the novel epinephrine product on solid ground.